New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer

Current Treatment Options in Oncology
Laird Cameron, B Solomon

Abstract

ALK rearrangements are present in 3-5% of patients with non-small cell lung cancer (NSCLC) and after epidermal growth factor receptor (EGFR) mutations represent the second molecular target in NSCLC to be validated through phase III clinical trials. The PROFILE 1014 international multicentre phase III trial demonstrated the superiority of crizotinib over standard chemotherapy, establishing crizotinib as standard first-line therapy for patients with advanced ALK-positive NSCLC and indicating the requirement for ALK testing to guide selection of optimal first-line therapy for non-squamous NSCLC. Despite impressive and durable responses, progression on treatment reflecting the development of acquired resistance is inevitable. There are several mechanisms of resistance including ALK kinase mutation or copy number gain, activation of bypass pathways and potentially pharmacokinetic failure of therapy (most commonly in CNS). A broad array of newer generation ALK inhibitors are in development that appear effective in the crizotinib-resistant setting including in patients with intracranial progression. These agents, including ceritinib and alectinib, have a higher potency against ALK kinase than crizotinib, activity against mutations tha...Continue Reading

References

Dec 10, 2008·Proceedings of the National Academy of Sciences of the United States of America·Manabu SodaHiroyuki Mano
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawA John Iafrate
Dec 17, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Benjamin SolomonD Ross Camidge
Oct 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistRonald Natale
Oct 29, 2010·The New England Journal of Medicine·Young Lim ChoiUNKNOWN ALK Lung Cancer Study Group
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Apr 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ryohei KatayamaAlice T Shaw
Jan 10, 2012·Bioorganic & Medicinal Chemistry·Kazutomo KinoshitaNobuhiro Oikawa
Jan 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C DoebeleD Ross Camidge
Jan 27, 2012·Science Translational Medicine·Ryohei KatayamaJeffrey A Engelman
Apr 5, 2012·Nature Reviews. Clinical Oncology·D Ross Camidge, Robert C Doebele
Jun 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Felip, A Martinez-Marti
Aug 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johannes M HeuckmannRoman K Thomas
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Andrew J WeickhardtD Ross Camidge
Apr 5, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark A SocinskiGeoffrey I Shapiro
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Nov 1, 2013·Science Translational Medicine·UNKNOWN Clinical Lung Cancer Genome Project (CLCGP), UNKNOWN Network Genomic Medicine (NGM)
Jan 31, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S-H I OuG J Riely
Mar 29, 2014·The New England Journal of Medicine·Alice T ShawJeffrey A Engelman
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
Apr 17, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sai-Hong Ignatius OuVincent A Miller
May 23, 2014·JAMA : the Journal of the American Medical Association·Mark G KrisPaul A Bunn
Jun 4, 2014·International Journal of Oncology·Antonio RossiCesare Gridelli
Jul 31, 2014·The Journal of Pharmacology and Experimental Therapeutics·Shinji YamazakiPaolo Vicini
Sep 1, 2014·Nature Medicine·Christine M LovlyWilliam Pao
Sep 11, 2014·Cancer Chemotherapy and Pharmacology·Tatsushi KodamaHiroshi Sakamoto
Sep 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaAlice T Shaw
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Oct 29, 2014·Molecular Cancer Therapeutics·Tatsushi KodamaHiroshi Sakamoto
Dec 2, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Benjamin Solomon

❮ Previous
Next ❯

Citations

Aug 9, 2016·BMC Cancer·Johanna S M MattssonMaria A Svensson
Oct 30, 2016·Trends in Pharmacological Sciences·Nicholas C Dracopoli, Mark S Boguski
Oct 24, 2018·Brain Tumor Pathology·Yoshiko NakanoKoichi Ichimura
Mar 10, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yayi HeFred R Hirsch
May 1, 2021·International Journal of Molecular Sciences·Daniela FerreiraRaquel Chaves
Sep 4, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Mingjing ShenYongbing Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.